Iraqi Journal of Microbiology and Biomedical Sciences
Published by the Iraqi Society for Microbiology
2026; 1(2):45-53 | www.iraqijmbs.org

REVIEW ARTICLE

The Role of Cytokine Storms and Inflammatory Cascades in Severe Bacterial Pneumonia

Mahmood Hayder Khalil [1]*, Omar Amir Salah-Aldeen [2]

[1,2] *Department of medical genetic, Iraqi center for cancer and medical genetic research, Baghdad, Iraq*

*** Correspondence:** mahmoodhaider94@uomustansiriyah.edu.iq

Received: [1/ 07/ 2026] Accepted: [5/8/2026] Published: [23/8/2026]

Publisher: Iraqi Society for Microbiology

Citation: M. H. Khalil and O. A. Salah-Aldeen, "The Role of Cytokine Storms and Inflammatory Cascades in Severe Bacterial Pneumonia," Iraqi Journal of Microbiology and Biomedical Science, vol. 1, no. 2, pp. 45–53, 2026.

ABSTRACT

Background: Severe bacterial pneumonia can trigger complex inflammatory cascades and cytokine storms. Initiated by the activation of pattern recognition receptors (PRRs) on alveolar macrophages, the dysregulated release of key pro-inflammatory mediators—prominently IL-6 and TNF-α—shifts the immune response from a protective host defense mechanism to a driver of catastrophic tissue injury. This hyper-inflammatory state frequently leads to severe complications, including acute respiratory distress syndrome (ARDS) and multi-organ dysfunction.

Objectives: To highlight the critical role of inflammatory cascades and to evaluate the essential use of molecular biomarkers for the timely detection and clinical management of severe bacterial pneumonia.

Methods: A narrative literature review was conducted using major scientific databases, including PubMed, Scopus, and Web of Science, to synthesize current evidence on the pathogenesis of cytokine storms in bacterial pneumonia and the clinical utility of key diagnostic and prognostic biomarkers.

Results: The review delineates the diagnostic, prognostic, and therapeutic value of current molecular markers in managing hyper-inflammatory states. Additionally, it identifies transformative future directions in biomarker research, emphasizing the integration of artificial intelligence (AI), machine learning, non-invasive liquid biopsies, and multi-omics approaches.

Conclusion: A better understanding of the interplay between immunological insults and complex pro- and anti-inflammatory markers is essential. Utilizing these insights will facilitate the transition toward personalized precision medicine for critically ill patients, thereby maximizing the efficacy of immunomodulatory treatments and improving survival outcomes.

Keywords: Severe bacterial pneumonia; personalized medicine; Cytokine storm; Diagnostic biomarkers; inflammatory cascade; Multi-omics.

1. INTRODUCTION

A cytokine storm is a pivotal and complex process in the immune response, especially in serious infections like bacterial pneumonia. During these storms, a massive surge of pro-inflammatory cytokines is released, which is required for the defense against infection but if not controlled, can cause extensive tissue damage and systemic complications. Important cytokines involved in this inflammatory cascade include IL-6 and TNF-α and are linked to higher mortality in those patients

with severe pneumonia [1]. These cytokines are not only markers of the intensity of inflammation, but they also predict negative outcomes of inflammation, such as the need for intensive care or mechanical ventilation. Knowing how to balance effective host defence and excessive inflammation is very important, as it will enable targeted therapeutic strategies to be developed, which can modulate the activity of cytokines and ultimately improve patient outcomes and decrease the risks of multi-organ dysfunction [1-2].

Furthermore, the kinetics of cytokine production, both temporal and quantitative, can be highly variable between persons, causing different clinical manifestations and prognosis of severe bacterial pneumonia. It has been seen, for example, that high levels of IL-6 and TNF-α at the outset of a disease are not only associated with more severe disease but also are associated with a higher risk of developing severe sepsis and multi-organ failure, at which point mortality rates can become alarming. [3]. This variability highlights the need for personalized treatment strategies, as monitoring cytokine levels could be used to tailor therapeutic interventions; for example, using anti-inflammatory drugs or immune modulators to restore balance might lead to better treatment outcomes and survival rates. Understanding patient-specific inflammatory profiles would help clinicians optimize the response to the damaging effects of cytokine storms and recovery pathways [4].

2. Pathogenesis of Severe Bacterial Pneumonia

Bacterial pneumonia is a serious disease characterized by inflammation of the lungs caused by bacteria. The pathogenesis starts with inhalation or aspiration of pathogenic bacteria, in this case Streptococcus pneumoniae or Staphylococcus aureus, which pass through the host's mucus barriers to infect alveoli [5]. Bacterial invasion induces activation of the immune system, involving alveolar macrophages and other immune cells, which recognize bacterial components through pattern recognition receptors (PRRs). This recognition initiates an inflammatory response with the production of pro-inflammatory cytokines such as IL-6 and TNF-α, leading to a cytokine storm. This is normal to help cells of the immune system migrate towards the area of infection, but this kind of excessive cytokine production can lead to damage to the tissues and to systemic problems, which makes pneumonia more serious [6]. The inflammatory response continues and neutrophils come to the site of infection, where they try to phagocytose the bacterium. But they can also secrete proteases and reactive oxygen species, which can cause further damage to the lungs. This damage may hinder the exchange of gases and even cause acute respiratory distress syndrome (ARDS) [6]. The systemic effects of the cytokine release may lead to multi-organ dysfunction and higher mortality. Individuals vary in the amount of cytokines produced, and this can result in different clinical pictures, with those who produce more likely to have more severe symptoms and complications. A deeper understanding of these mechanisms is crucial for the development of targeted therapeutic strategies that would allow modulation of the inflammatory response and, ultimately, improve patient outcomes and decrease risk from severe bacterial pneumonia [7].

3. The Inflammatory Cascade and Key Mediators

With the evolution of the inflammatory cascade, the importance of the other mediators of the immune system grows, especially in the case of severe pneumonia. Pro-inflammatory cytokines and anti-inflammatory mediators, for example, can play a particularly important role in the resolution of the inflammatory process and mechanisms of repair. Research has shown that those patients who display

a compromised or balanced (not too much or too little) cytokine profile, including sufficient amounts of the regulatory cytokine, IL-10, and pro-inflammatory cytokines, have more favorable clinical outcomes and that the regulation of the immune response would diminish the negative consequences of excessive inflammatory activity. [8]. Moreover, novel studies reveal the possibility of targeting specific pathways engaged in the signaling of cytokines, such as the JAK-STAT pathway, as a potential pathway for new therapeutic strategies in severe pneumonia and to minimize multi-organ dysfunction. [9] [10]. The new insights gained from understanding these intricate interactions could help develop treatments that not only help fight infection but also accelerate healing and prevent complications down the road.

The medical and clinical community will be in a much more advantageous position to be well equipped to design targeted interventions, which not only will help combat and eliminate various types of infections, but also will be helpful in supporting a more robust recovery process, while minimizing the risk for long term complications that could have a negative impact on patient health down the road [1-5].



Figure 1: Intracellular signaling pathways of key pro-inflammatory cytokines (IL-1, TNF-α, and IL-6) leading to altered gene expression during inflammatory responses [11].

4. Clinical Biomarkers in Severe Bacterial Pneumonia

Relying on isolated markers is insufficient for managing complex cases of severe pneumonia; hence, a comprehensive evaluation of diagnostic, severity, prognostic, and therapeutic-response biomarkers is essential.

Diagnostic and Severity Biomarkers: C-reactive protein (CRP) and procalcitonin (PCT) remain the cornerstone for diagnosing bacterial infections. While CRP is highly sensitive to systemic inflammation, PCT offers superior specificity for bacterial etiologies, making it a critical tool for diagnostic confirmation and antibiotic stewardship [12]. Presepsin (sCD14-ST), a soluble CD14 subtype released by macrophages, has emerged as a reliable and rapid diagnostic marker for bacterial sepsis. In addition to primary cytokines like IL-6 and TNF-α, which are central to severity stratification, IL-1β and IL-8 play crucial roles; IL-1β acts as a potent amplifier of inflammation, while IL-8 drives massive neutrophil influx into the lungs. Conversely, IL-10 is a vital anti-

inflammatory cytokine, and its balance with pro-inflammatory mediators often dictates clinical severity.

Prognostic and ARDS/Endothelial Injury Markers: In the intensive care setting, prognostic biomarkers are critical for predicting clinical deterioration. The Neutrophil-to-Lymphocyte Ratio (NLR) serves as a simple, cost-effective cellular marker reflecting the imbalance between innate and adaptive immunity. Elevated levels of lactate indicate tissue hypoperfusion and impending septic shock, while hyperferritinemia (elevated ferritin) is a hallmark of macrophage activation syndrome and severe systemic inflammation. The coagulation-inflammation interplay is best monitored using D-dimer, where elevated levels are strongly associated with micro-thrombosis. Furthermore, markers of severe endothelial injury and ARDS, such as angiopoietin-2 and syndecan-1, provide deep insights into vascular barrier breakdown. Soluble TREM-1 (sTREM-1) and suPAR are also highly accurate in predicting poor outcomes, mechanical ventilation requirements, and mortality in severe community-acquired pneumonia [13].

5. The Role of Biomarkers in Disease Diagnosis: Mechanisms and Applications:

Biomarkers are measurable characteristics that provide information about biological or pathogenic processes, or response to therapeutic modalities. Their importance in the diagnosis of diseases is tremendous since they can help determine essential functions of various diseases, which can lead to early diagnosis, prognosis, and follow-up effectiveness. Biomarkers play a key role in understanding the pathology of diseases. Biomarker applications to the clinic are far-reaching. They are a crucial part of early detection of diseases, which is essential for timely intervention. Furthermore, biomarkers play an important role in assessment of disease progression and treatment effectiveness [12]. Based on this information, health care can optimize timely adjustments to treatment plans, ensuring optimal patient care and management. To summarise, the importance of biomarkers for disease diagnosis is great. They provide insights into mechanisms, which can lead to a better understanding of different health conditions and to practical uses that can improve patient care. With additional research identifying new biomarkers and their participation in diseases, the possibilities for new advances in diagnostic methods and treatment will continue to grow. This advancement is essential in the realm of modern medicine, as it could lead to better health outcomes for patients around the world, highlighting the critical role of biomarkers in medical research [13].

6. Evaluating the Diagnostic Utility of Biomarkers: Key Metrics and Methodologies

Today, the assessment of a biomarker is of critical importance in the field of modern medicine, especially in diagnostics and personalized medicine. Biomarkers, defined as biological markers indicative of a disease state or condition, are vital for the early detection, diagnosis, and monitoring of diseases such as cancer, cardiovascular diseases, and even infectious diseases. It is crucial to have strong methodologies and metrics to evaluate and ensure that these are effective and reliable [1] [14]. Sensitivity is one of the main parameters used to evaluate the diagnostic value of a biomarker and is defined as the proportion of people with the disease who test positive (true positive) by the test. Sensitivity is important, especially for screening tests because they will have fewer false negatives. Specificity on the other hand, is another important measure that tests the ability of the test to correctly identify people without the disease (true negatives). A balance between sensitivity and specificity is

crucial for the overall effectiveness of a biomarker [15]. Positive predictive value (PPV) and negative predictive value (NPV) are other measures that offer understanding of the utility of biomarkers in the clinical arena. PPV shows the probability that people who test positive are actually positive for the disease, and NPV shows the probability that people who test negative are actually negative for the disease. The prevalence of the disease in the population being tested affects these values, so they must be considered when interpreting the results [16]. There are several different methodologies used for the evaluation of biomarkers, but the most common include clinical studies, statistical analysis, and validation processes. Three common designs for evaluating biomarker performance are cohort studies, case-control studies, and randomized controlled trials. These studies should be designed to reduce bias and confounding factors and provide reliable and relevant results for the target population [17]. In addition, receiver operating characteristic (ROC) curves have become a common method to assess the diagnostic value of biomarkers. ROC curves enable a researcher to view the sensitivity and specificity trade-off for different threshold values and to determine the clinically appropriate threshold value. In recent years, biomarker discovery and validation has been extended by the incorporation of new technologies including genomics and proteomics [18]. But because of the complexity of biological systems, careful evaluation needs to be performed to confirm that these new biomarkers will give meaningful clinical information. The ethical parameters of biomarker testing, including consent issues and privacy of test data and the potential psychological impact of test results, should also be considered. Finally, knowledge of key metrics like sensitivity, specificity, PPV and NPV, as well as robust methodologies which allow reliable and applicable findings of the diagnostic utility of biomarkers, is required. Biomarkers hold significant promise for improving diagnostics and, ultimately, patient outcomes in the field. As it continues to develop, research and development will be essential to further advancing the capabilities of biomarkers and more personalized healthcare. [19].



Figure 2. A comprehensive workflow for the discovery and validation of novel biomarkers, transitioning from diverse multi-omics approaches to targeted clinical validation [20].

7. Future Directions in Biomarker Research: Innovations and Emerging Technologies

In recent years, there has been substantial progress in the field of biomarker research, fuelled by the desire to obtain more accurate diagnostics, make personalized medicine a reality and develop better therapeutic approaches. Recently, a few innovations and new technologies will change the biomarker discovery and applications game [21]. One of the most promising areas of development is in the integration of artificial intelligence (AI) and machine learning in biomarker research. These technologies help scientists process large amounts of data, look for patterns and make predictions with greater accuracy than ever before. AI algorithms can be used to analyze vast amounts of data from genomics, proteomics, and metabolomics, leading to the identification of new biomarkers that would have otherwise stayed unnoticed [22]. Such a capability not only speeds up the discovery process, but also makes it possible to improve the validation of biomarkers so that only the most relevant ones will be pursued for clinical application. Liquid biopsies are another fascinating development that provides an alternative to conventional tissue biopsies, which are non-invasive. Liquid biopsies are tests of circulating tumor DNA (ctDNA), exosomes, and other biomarkers in bodily fluids like blood or urine. This will help monitor the disease in real time and adjust therapy accordingly. Liquid biopsies offer valuable information on a patient's health status without the invasive procedures, which could make it a standard practice in oncology and other fields as technology continues to develop [15]. The advent of multi-omics technologies is also revolutionizing biomarker research. Combining information from genomics, transcriptomics, proteomics and metabolomics can provide a holistic view of biological systems and mechanisms underlying diseases. This holistic approach will allow for the identification of biomarkers that possess a comprehensive understanding of human biology, enabling more effective and personalized treatment options. With the increasing availability and cost-effectiveness of multi-omics platforms, their usage in the clinical setting is likely to increase, allowing for more precise diagnosis and treatment of diseases [23]. Furthermore, the development of technology in biotechnology, including CRISPR technology and other gene editing technologies, increases the potential for biomarker development. These technologies offer the ability to manipulate the genetic material with precision, allowing the researchers to explore the functional aspects of specific genes and their corresponding biomarkers. Scientists can use the information to gain insight into the biological mechanisms behind the disease, discover new targets for drug development, and create markers to determine if a drug is successful or if it has side effects [15]. Another key element of innovation in biomarker research is that cross-disciplinary collaborations are important. Collaborators from various disciplines, including genomics, bioinformatics, and clinical medicine, can exchange ideas and approaches, leading to improved biomarker identification. Cooperation, such as joint projects or public-private partnerships and consortia, is vital to share resources and expertise and to move research into clinical practice. In conclusion, the future of biomarker research looks promising, with continued technological advancements and a collaborative effort driving innovation in the field. AI, liquid biopsies, multi-omics, and state-of-the-art biotechnologies are poised to revolutionize the understanding and use of biomarkers [24-25]. As these innovations continue to unfold, they have the potential to enhance patient outcomes through more precise diagnostics, personalized treatment approaches, and a better understanding of the biology of disease. Continued efforts in research and collaboration will play a crucial role in unlocking the potential of biomarkers in healthcare [26-27].

8. Conclusion

Ultimately, the clinical course and outcome of severe bacterial pneumonia depend largely on the balance between clearance of the pathogen and inflammatory tissue damage by the host. The exaggerated production of cytokine storms worsens alveolitis and can lead to life-threatening multi-organ failure. While the modulation of these biological pathways and the systematic use of well-validated biomarkers hold tremendous potential for personalized medicine, their routine clinical implementation currently faces significant limitations. These include high costs, the lack of universally standardized cut-off values due to patient heterogeneity, and the required turnaround time for complex multi-omics analyses. Looking ahead, state-of-the-art technologies such as AI-powered data analysis and circulating biomarkers are poised to facilitate high-fidelity biomarker discovery. However, cautious, evidence-based approaches and large-scale prospective validation studies are essential before these tools can be universally adopted at the bedside to reliably predict clinical deterioration and guide targeted immunomodulatory therapies.

ACKNOWLEDGMENT

The authors would like to express their sincere to Al-Mustansiriyah University for their continuous academic support and for providing the necessary resources to complete this work.

CONFLICT OF INTEREST

The authors declared no conflict of interest.

AUTHOR CONTRIBUTIONS

The first Author conceptualized the idea for this review, performed the primary literature search regarding cytokine storms and inflammatory cascades, and drafted the initial manuscript, while the second Author assisted in the literature review, provided clinical insights on severe bacterial pneumonia, and critically revised the manuscript for important intellectual content. Both authors read and approved the final version of the manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ETHICS APPROVAL AND CONSENT TO PARTICIPATE

No ethical approval is required.

REFERENCES

1. Kellum JA, Kong L, Fink MP, Weissfeld LA, Yealy DM, Pinsky MR, et al. Understanding the inflammatory cytokine response in pneumonia and sepsis: results of the Genetic and Inflammatory Markers of Sepsis (GenIMS) Study. JAMA Intern Med. 2007; 167: 1655–1663.
2. Neupane B, Devkota MD, Pokhrel BM, Rimal S, Banjara MR. Phenotypic characteristics and carbapenemase genes in Klebsiella pneumoniae from patients at Upendra Devkota Memorial National Institute of Neurological and Allied Sciences, Kathmandu, Nepal. BMC Infect Dis. 2025; 25.
3. Zeng J, He Z, Wang G, Ma Y, Zhang F. Interaction between microbiota and immunity: molecular mechanisms, biological functions, diseases, and new therapeutic opportunities. MedComm. 2025; 6(7): e70265. doi: 10.1002/mco2.70265.
4. Zheng D, Liwinski T, Elinav E. Interaction between microbiota and immunity in health and disease. Cell Res. 2020.

5. Belkaid Y, Hand TW. Role of the microbiota in immunity and inflammation. Cell. 2014; 157(1): 121–141.
6. Ullah H, Arbab S, Tian Y, Chen Y, Liu CQ, Li Q, et al. Crosstalk between gut microbiota and host immune system and its response to traumatic injury. Front Immunol. 2024.
7. Calbo E, Alsina M, Rodríguez-Carballeira M, Lite J, Garau J. Systemic expression of cytokine production in patients with severe pneumococcal pneumonia: effects of treatment with a β-lactam versus a fluoroquinolone. Antimicrob Agents Chemother. 2008; 52: 2395–2402.
8. Fernández-Serrano S, Dorca J, Coromines M, Carratalà J, Gudiol F, Manresa F. Molecular inflammatory responses measured in blood of patients with severe community-acquired pneumonia. Clin Vaccine Immunol. 2003; 10: 813–820.
9. Volchkova E, Titova O, Kuzubova N, Lebedeva E. Potential predictors of severe course and outcome of community-acquired pneumonia. Pulmonologiia. 2023; 33: 225–232.
10. Tanaka Y. A review of Janus kinase inhibitors for the treatment of COVID-19 pneumonia. Inflamm Regen. 2023; 43.
11. Mbanefo EC, Le L, Zee R, Banskota N, Ishida K, Pennington LF, et al. IPSE, a urogenital parasite-derived immunomodulatory protein, ameliorates ifosfamide-induced hemorrhagic cystitis through downregulation of pro-inflammatory pathways. Sci Rep. 2019; 9(1): 1586. doi: 10.1038/s41598-018-38274-z.
12. Schuetz P, Beishuizen A, Broyles M, Ferrer R, Gavazzi G, Gluck EH, et al. Procalcitonin (PCT)-guided antibiotic stewardship: an international experts consensus on optimized clinical use. Clin Chem Lab Med. 2019; 57(9): 1308–1318.
13. Zheng M, Zhang P, Ding J. Prognostic value of sTREM-1 in severe pneumonia: a systematic review and meta-analysis. Sci Rep. 2021; 11(1): 21051.
14. Wilkinson NJ, Smith MAA, Kay RW, Harris RA. A review of aerosol jet printing: a non-traditional hybrid process for micro-manufacturing. Int J Adv Manuf Technol. 2019.
15. Soni S, Rathee S, Jain SK. Biomarkers as drivers of innovation in modern diagnostics and therapeutics. Curr Drug Targets. 2026; 27(7): 452–466. doi: 10.2174/0113894501419834251129045230.
16. Zoccali C, Tripepi G, Stel V, Fu EL, Mallamaci F, Dekker F, Jager KJ. Biomarkers in clinical epidemiology studies. Clin Kidney J. 2024; 17(6): sfae130. doi: 10.1093/ckj/sfae130.
17. Bergman N, Bergquist J. Recent developments in proteomic methods and disease biomarkers. Analyst. 2014; 139(16): 3836–3851. doi: 10.1039/C4AN00807E.
18. Ahmad A, Imran M, Ahsan H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics. 2023; 15(6): 1630. doi: 10.3390/pharmaceutics15061630.
19. Bossuyt PMM. Defining biomarker performance and clinical validity. J Med Biochem. 2011; 30: 193–200.
20. Califf RM. Biomarker definitions and their applications. Exp Biol Med (Maywood). 2018; 243(3): 213–221. doi: 10.1177/1535370217750088.
21. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther. 2013; 93(3): 252–259. doi: 10.1038/clpt.2012.237.
22. Alwan FM, Sayel RA. Epidemiological characteristics of intestinal parasitic and bacterial infections and community surveillance barriers in Diyala Governorate, Iraq. Adolesc Saude. 2026; 21(4 Suppl): 440–448.
23. Del Boccio P, Rossi C, Di Ioia M, Cicalini I, Sacchetta P, Pieragostino D. Integration of metabolomics and proteomics in multiple sclerosis: from biomarkers discovery to personalized medicine. Proteomics Clin Appl. 2016; 10(4): 470–484. doi: 10.1002/prca.201500083.
24. Ahmad A, Imran M, Ahsan H. Biomarkers as biomedical bioindicators: approaches and techniques for the detection, analysis, and validation of novel biomarkers of diseases. Pharmaceutics. 2023; 15(6): 1630.

25. Gopal GV, Kanakaprabha S, Rao GM, Raju YR, Kumar GG. Disease biomarker discovery with big data analysis. In: Intelligent Data Analytics for Bioinformatics and Biomedical Systems. 2024. p. 313–330.
26. Molla G, Bitew M. Revolutionizing personalized medicine: synergy with multi-omics data generation, main hurdles, and future perspectives. Biomedicines. 2024; 12(12): 2750.
27. Goldman M, Compton CC, Mittleman BB. Public-private partnerships as driving forces in the quest for innovative medicines. Clin Transl Med. 2013; 2: 2.